DAJY(SZ:002030) Cai Jing Wang·2026-02-02 13:47Core Viewpoint - Da An Gene (002030) expects a net profit loss attributable to shareholders of approximately 607 million to 865 million yuan for the fiscal year 2025, showing improvement compared to a loss of 925 million yuan in the same period last year [1] Group 1: Financial Performance - The main reasons for the performance change include a decrease in operating revenue due to market demand and adjustments in the value-added tax rate for self-produced reagent products [1] - The company has implemented various cost-saving measures to enhance operational efficiency, but the fixed costs such as operational and labor costs remain high, making it difficult for the revenue decline to match the cost reduction in the short term, negatively impacting the overall gross profit [1] Group 2: Investment and Earnings - During the reporting period, the performance of the company's joint ventures improved compared to the previous year, leading to an increase in investment income recognized from joint ventures [1] - The net profit attributable to shareholders of the listed company increased compared to the same period last year [1]